Author/Authors :
Ebrahimi Daryani, Nasser tehran university of medical sciences tums - Department of Gastroenterology and Hepatology, تهران, ايران , Alavian, Moayed baqiyatallah university of medical sciences - Baqiyatallah Research Center for Gastroenterology and Liver Diseases, ايران , Alavian, Moayed Middle East Liver Diseases Center (MELD), ايران , Somi, Mohammad Hossein tabriz university of medical sciences - Research Center for Gastroenterology and Liver Diseases, ايران , Torabi-Nami, Mohammad shiraz university of medical sciences - School of Advanced Medical Science and Technologies, ايران
Abstract :
The cross-border symposium on hepatitis C, entitled “why treating now?” was held on 15th May 2013 during the 5th International Tehran Hepatitis Congress. The present report summarizing communicated insights during this symposium is intended to help health care providers to make well-informed decisions when treating patients with chronic hepatitis C (CHC). Since today’s evolving science of hepatitis C management has introduced new treatment options, one should be well-versed about the potential benefits as well as untoward effects or practical challenges when using these regimens. In addition to outline HCV treatment advances, this symposium focused on the central question that why eligible patients with hepatitis C who may mostly benefit from the currently available protease inhibitors, should be treated now rather than be waited for the future therapies. Moreover, an overview of long term local experience with protease inhibitors in our challenging hepatitis C patients was presented during this interactive symposium.
Keywords :
Hepatitis C , Protease Inhibitors , Management , Iran
